Jasper Therapeutics Announces Board Resignation and Committee Change

Jasper Therapeutics ( (JSPR) ) just unveiled an announcement.

On May 15, 2026, Jasper Therapeutics, Inc. announced that board member Christian Nolet resigned from the Board of Directors and all board committees, with the company emphasizing that his departure did not stem from any disagreement over its operations, policies or practices. The Board simultaneously strengthened its governance structure by appointing Svetlana Lucas, Ph.D., to the Audit Committee, signaling a continued focus on maintaining experienced oversight of the company’s financial and compliance functions.

The most recent analyst rating on (JSPR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Spark’s Take on JSPR Stock

According to Spark, TipRanks’ AI Analyst, JSPR is a Neutral.

The score is weighed down primarily by weak financial performance (pre-revenue losses, significant ongoing cash burn, and a sharply reduced equity base that heightens funding sensitivity). Technicals add further pressure due to a broader downtrend and negative MACD. Valuation contributes only modestly because P/E is not meaningful for a loss-making company and there is no dividend yield support.

To see Spark’s full report on JSPR stock, click here.

More about Jasper Therapeutics

Jasper Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing therapies that leverage hematopoietic stem cell biology. The company targets serious diseases where stem cell-based treatments can offer curative potential, positioning itself within a competitive and innovation-driven segment of the life sciences market.

Average Trading Volume: 401,547

Technical Sentiment Signal: Sell

Current Market Cap: $24.42M

For a thorough assessment of JSPR stock, go to TipRanks’ Stock Analysis page.